> Already, seniors make up 26.6 percent of the people who have been prescribed these and other GLP-1 agonists, including Ozempic, since 2018, according to a report from Truveta, which draws data from a large network of health-care systems.
> In the coming years, that proportion could rise even higher: The bipartisan Treat and Reduce Obesity Act, introduced in Congress last July, would allow Medicare to cover drug treatments for obesity among its roughly 50 million Part D enrollees above the age of 65; in principle, about two-fifths of that number would qualify as patients.
I did not know this and was pretty shocked. Of course I don't object to it, but didn't know this had happened already.
Also, the WHO is possibly going to put Liraglutide (Victoza/Saxenda) on the Essential Medicines List[0].